questionText: To ask the Secretary of State for Health and Social Care, with reference to NHS England’s publication entitled Interim commissioning guidance: Implementation of the NICE Technology Appraisal TA1026 and the NICE funding variation for tirzepatide (Mounjaro) for the management of obesity, published on 27 March 2025, what estimate (a) NHS England and (b) the National Institute for Health and Care Excellence have made of the number of patients eligible for Mounjaro in each year from 2025-26 to 2027-28.
answerText: The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing evidence-based guidance for the National Health Service on the use of licensed medicines based on an assessment of their clinical and cost-effe...
heading: Tirzepatide